Want to see HK:1312 full AI Analyst Report?
1312 Stock Chart & Stats
HK$0.03
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.03
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.02 - HK$0.04
Previous CloseN/A
Volume162.00K
Average Volume (3M)358.80K
Market Cap
HK$150.63M
Enterprise ValueHK$186.41M
Total Cash (Recent Filing)HK$67.62M
Total Debt (Recent Filing)HK$189.76M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.96%
Share Statistics
EPS (TTM)-0.04
Shares Outstanding5,588,572,000
10 Day Avg. Volume38,400
30 Day Avg. Volume358,800
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.18
P/FCF Ratio3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsConsistently high gross margins indicate that the company retains meaningful value after direct costs, supported by pricing or product-mix advantages stated in the financial analysis. If maintained, this provides a foundation for restoring operating profitability once cost control and operating leverage improve.
Improving Cash GenerationPositive operating and free cash flow over the latest three years, together with the strong 2025 step-up, improves the company’s ability to fund operations internally. This can reduce reliance on external financing and provide greater flexibility while profitability remains under pressure.
Lower LeverageThe substantial reduction in debt relative to equity lowers balance-sheet leverage and should reduce financial risk compared with earlier periods. A less leveraged structure gives management more capacity to withstand operating weakness and allocate future cash toward business needs rather than debt burdens.
Bears Say
Deepening Net LossesThe sharp deterioration in net profitability is a durable concern because it directly weakens retained equity and limits the company’s ability to reinvest from earnings. Unless the underlying costs, charges, or operating inefficiencies improve, recurring losses could continue to erode financial resilience.
Weak Operating ProfitabilityNegative EBIT and EBITDA show that gross profit is not currently sufficient to cover operating costs and other expenses. This disconnect limits the benefit of the company’s strong gross margins and indicates that sustainable earnings recovery depends on materially improving operating leverage or reducing the cost base.
Cash Flow Quality RiskRecent cash generation is encouraging, but its reliability is weakened by the company’s continuing losses, the stated lack of dependable 2025 cash-flow metrics tied to net income, and earlier negative free cash flow. This makes sustained self-funded growth less certain until earnings and cash converge.
Kontafarma China Holdings Ltd News
1312 FAQ
What was Kontafarma China Holdings Ltd’s price range in the past 12 months?
Kontafarma China Holdings Ltd lowest stock price was HK$0.02 and its highest was HK$0.04 in the past 12 months.
What is Kontafarma China Holdings Ltd’s market cap?
Kontafarma China Holdings Ltd’s market cap is HK$150.63M.
When is Kontafarma China Holdings Ltd’s upcoming earnings report date?
Kontafarma China Holdings Ltd’s upcoming earnings report date is Apr 01, 2027 which is in 151 days.
How were Kontafarma China Holdings Ltd’s earnings last quarter?
Kontafarma China Holdings Ltd released its earnings results on Aug 28, 2026. The company reported -HK$0.012 earnings per share for the quarter.
Is Kontafarma China Holdings Ltd overvalued?
According to Wall Street analysts Kontafarma China Holdings Ltd’s price is currently Overvalued.
Does Kontafarma China Holdings Ltd pay dividends?
Kontafarma China Holdings Ltd pays a Annually dividend of HK$0.004 which represents an annual dividend yield of 2.96%. See more information on Kontafarma China Holdings Ltd dividends here
What is Kontafarma China Holdings Ltd’s EPS estimate?
Kontafarma China Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kontafarma China Holdings Ltd have?
Kontafarma China Holdings Ltd has 5,588,572,000 shares outstanding.
What happened to Kontafarma China Holdings Ltd’s price movement after its last earnings report?
Kontafarma China Holdings Ltd reported an EPS of -HK$0.012 in its last earnings report. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Kontafarma China Holdings Ltd?
Currently, no hedge funds are holding shares in HK:1312
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kontafarma China Holdings Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.89%
12-Months-Change
Fundamentals
Return on Equity
-40.02%
Trailing 12-Months
Asset Growth
-13.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kontafarma China Holdings Ltd
Kontafarma China Holdings Ltd. directs its business efforts through two principal segments: Pharmaceutical and Fitness. Its Pharmaceutical arm is responsible for the manufacturing and marketing of prescription medications and associated laboratory goods. Meanwhile, the Fitness division oversees the management of health clubs, delivers advisory services for physical well-being and health-related pursuits, and runs a franchise model to generate royalty revenue. Established on March 21, 2011, the company maintains its corporate headquarters in Hong Kong.
Technical Analysis
China National Building Material Co
―
Xinyi Glass Holdings
―
China Glass Holdings Limited
―
China Tianrui Group Cement Co., Ltd.
―
YCIH Green High-Performance Concrete Co., Ltd. Class H
―